CELINE MARTIN ROGER DALBERT

About CELINE MARTIN ROGER DALBERT

Céline Roger-Dalbert is one of the key executives at bioMérieux, the globally listed in vitro diagnostics company. She joined the group in August 2022 as Senior Vice President, R&D Clinical and Regulatory Affairs, and was later appointed Executive Vice President, Research and Development, effective March 1, 2024. In this role, she leads the R&D function and the company’s innovation strategy, which bioMérieux presents as one of the core pillars of its growth and long-term differentiation. As a member of the Executive Committee, she occupies a strategic position at the intersection of science, regulation, and product development. Her remit includes accelerating innovation, strengthening the performance of microbiology and molecular biology solutions, integrating new technologies, and expanding scientific partnerships. bioMérieux highlights her role in working with hospitals, laboratories, and research partners to develop solutions that better reflect real-world clinical needs. Visible examples of her leadership include bioMérieux’s partnership with Mila to apply artificial intelligence to diagnostics, as well as initiatives aimed at expanding next-generation sequencing capabilities and advancing infectious disease diagnostics. These moves point to a clear strategic direction: combining scientific expertise, data, software, and faster diagnostic pathways to improve patient care. In the context of listed-company governance, her profile reflects high-level expertise in research and development, regulatory affairs, and the transformation of the diagnostic portfolio. Her mission is to build a value-generating innovation pipeline, secure regulatory pathways, and accelerate the market introduction of solutions designed to address major public-health challenges, especially infectious diseases and antimicrobial resistance.